When facing a gastrointestinal stromal tumor, understanding your treatment options can help you feel more in control during a challenging time. These rare tumors, which form in the digestive system, are now more manageable than ever thanks to advances in both surgical techniques and targeted medications that work at the molecular level.

How Treatment Approaches Are Changing the Outlook for GIST Patients

Treating gastrointestinal stromal tumors involves more than just removing a growth. The main goals include stopping the tumor from growing, preventing it from spreading to other parts of the body, managing symptoms that affect daily life, and giving patients the best chance at long-term survival. Each person’s treatment plan is unique, shaped by factors such as the size of the tumor, where it is located in the digestive tract, whether it has spread, the patient’s overall health, and importantly, the genetic makeup of the tumor itself.^[9]

Modern medicine recognizes that not all gastrointestinal stromal tumors behave the same way. Some grow slowly and may never cause serious problems, while others are aggressive and require immediate intervention. Medical societies around the world have developed treatment guidelines based on years of research and clinical experience. These standards help doctors decide whether surgery alone is enough, or if medications should be added before or after an operation.^[11]

Beyond the established treatments that doctors use routinely, there is ongoing research into new therapies through clinical trials—carefully monitored studies where experimental drugs are tested in people. These trials offer hope for patients whose tumors have stopped responding to standard treatments, and they also help scientists understand which approaches work best for different types of gastrointestinal stromal tumors.^[9]

Standard Treatment: Surgery and Targeted Therapy

When a gastrointestinal stromal tumor is detected and can be completely removed, surgery is usually the first choice. The goal is to take out the entire tumor along with a border of healthy tissue around it, which doctors call a clear margin. Having clear margins means no cancer cells are left at the edge of what was removed, which lowers the chance of the tumor coming back. For tumors in the stomach, surgeons might need to remove part or all of the stomach. If the tumor is in the small intestine, the affected section is taken out. In some cases, nearby organs like the spleen may also need to be removed if the tumor has grown close to them.^[12][14]

Surgery for gastrointestinal stromal tumors requires careful technique. The tumor should be handled gently because if it breaks open during the operation, cancer cells can spread into the abdomen. This is why experienced surgeons aim to remove the tumor in one piece. Many operations can now be done using laparoscopic or robotic surgery, which means smaller incisions, less pain afterward, and faster recovery. These minimally invasive techniques are especially helpful for smaller tumors in accessible locations.^[16]

After surgery, doctors assess the risk of the tumor returning. This assessment considers the original size of the tumor, how many cells were dividing rapidly (the mitotic rate), where in the digestive tract it was located, and whether it had ruptured. Patients at higher risk are usually offered additional treatment with medication to reduce the chance of the cancer coming back.^[11][17]

The most important drug for treating gastrointestinal stromal tumors is imatinib, sold under the brand name Gleevec. This medication belongs to a class called tyrosine kinase inhibitors, which block specific proteins that tell tumor cells to grow and multiply. Most gastrointestinal stromal tumors have a change, or mutation, in a gene called KIT, which causes cells to produce too much of a growth-signaling protein. Imatinib works by blocking this signal, essentially turning off the switch that tells the tumor to grow.^[12][19]

The decision to use imatinib depends on genetic testing of the tumor. Tumors with certain KIT mutations, particularly those in exon 11, respond very well to imatinib—about 90% of patients with this mutation see their tumors shrink or stop growing. Tumors with mutations in exon 9 of KIT are somewhat less sensitive, and doctors may recommend a higher dose in these cases. Some tumors have mutations in a different gene called PDGFRA, and most of these also respond to imatinib, except for one specific mutation called D842V, which is naturally resistant to this drug.^[19][17]

When imatinib is used after surgery to prevent recurrence, it is called adjuvant therapy. The standard duration is typically three years for higher-risk tumors, though some patients may benefit from longer treatment. Imatinib can also be given before surgery—called neoadjuvant therapy—to shrink a large or difficult-to-remove tumor, making the operation safer and more likely to be successful.^[19][17]

The usual starting dose of imatinib is 400 milligrams once daily, taken as a pill. If needed, the dose can be increased to 800 milligrams per day. Most people tolerate imatinib reasonably well, though side effects do occur. Common ones include swelling around the eyes or in the legs, skin rash, diarrhea, nausea, stomach discomfort, muscle cramps, and fatigue. More serious but less common side effects include liver problems, which is why doctors monitor blood tests regularly during treatment. If side effects become severe, the dose can be reduced or treatment temporarily paused.^[19][12]

If a tumor grows despite imatinib treatment, or if a patient cannot tolerate imatinib, the next medication typically used is sunitinib (brand name Sutent). Sunitinib works similarly to imatinib but blocks a slightly different set of growth signals. It can also block the formation of new blood vessels that tumors need to grow, which is called an antiangiogenic effect. Sunitinib is usually given in cycles, with four weeks on the medication followed by two weeks off. Side effects include fatigue, changes in skin and hair color (turning yellow), diarrhea, hand-foot syndrome (painful redness and swelling of palms and soles), and high blood pressure.^[19][14]

If the tumor continues to progress after both imatinib and sunitinib, a third medication called regorafenib (brand name Stivarga) may be used. Like the others, regorafenib is a tyrosine kinase inhibitor that blocks multiple growth signals. It has been shown to slow tumor growth in patients who have already tried other treatments. The most common side effects include hand-foot syndrome, fatigue, diarrhea, high blood pressure, and loss of appetite.^[14][19]

Treatment in Clinical Trials: New Hope for Resistant Tumors

Even with the success of imatinib, sunitinib, and regorafenib, some gastrointestinal stromal tumors eventually stop responding to these drugs. This is called resistance, and it can happen because the tumor develops new genetic mutations that allow it to keep growing despite the medication. For these patients, clinical trials offer access to newer drugs that might work when standard treatments fail.^[9]

One of the promising newer medications is ripretinib, which was approved in 2020 specifically for patients who have already received three or more previous treatments for advanced gastrointestinal stromal tumor. Ripretinib is designed to work differently from earlier drugs—it is sometimes called a “switch-control” kinase inhibitor because it can block the growth signals even when the tumor has developed resistance mutations. In clinical trials, ripretinib was tested in Phase I studies to find the safe dose, then in Phase II studies to see how well it worked in a small group of patients, and finally in a Phase III trial that compared it to a placebo (inactive pill) in patients with resistant tumors. The Phase III trial showed that ripretinib significantly slowed tumor growth compared to placebo, giving patients more time before their disease worsened.^[19]

Another medication being studied is avapritinib, which is particularly interesting for tumors with the PDGFRA D842V mutation—the type that does not respond to standard imatinib therapy. Avapritinib was specifically designed to target this mutation. Early clinical trials (Phase I and II) showed that about 90% of patients with the D842V mutation responded to avapritinib, with many seeing their tumors shrink substantially. This drug represents an important breakthrough for a group of patients who previously had very limited options. Clinical trials of avapritinib are being conducted in the United States, Europe, and other regions.^[17]

Researchers are also exploring combinations of different drugs. For example, some trials are testing whether adding drugs that boost the immune system—called immunotherapy—to tyrosine kinase inhibitors might improve outcomes. Other studies are looking at drugs that target the blood vessels feeding the tumor, or that block other molecular pathways involved in tumor growth. These trials are typically in Phase I or Phase II, meaning they are still in the early stages of testing safety and effectiveness.^[9]

Clinical trials follow a careful process. Phase I trials mainly look at safety and the right dose to use. They usually involve a small number of patients. Phase II trials test whether the drug actually works—does it shrink tumors or slow their growth? These studies involve more patients but are still relatively small. Phase III trials are large studies that compare the new drug to the current standard treatment or to a placebo. Only after a drug succeeds in Phase III is it typically approved for general use. Phase IV studies happen after approval and continue to monitor the drug’s long-term safety and effectiveness in a broader population.^[9]

Some tumors are particularly challenging. Gastrointestinal stromal tumors that occur in people with certain inherited conditions, such as tumors lacking a functional SDH enzyme (called SDH-deficient GIST), tend to be resistant to standard tyrosine kinase inhibitors. These tumors often appear in younger patients and may occur along with other types of tumors. Researchers are studying whether drugs with strong anti-blood-vessel effects might work better for this subtype. Because these cases are rare and complex, doctors often recommend that patients with SDH-deficient tumors be referred to specialized cancer centers that have experience managing this variant.^[19][8]

Another area of research involves understanding why some tumors become resistant to drugs over time. Scientists have discovered that resistance often happens because the tumor develops additional mutations while being treated. By identifying these resistance mutations through repeated biopsies or blood tests (called liquid biopsies), doctors may be able to switch to a different drug that targets the new mutation. This approach, called precision medicine, tailors treatment to the exact genetic profile of each patient’s tumor as it evolves.^[11]

Most common treatment methods

• Surgery
  • Complete removal of the tumor with clear margins is the primary treatment for localized gastrointestinal stromal tumors and offers the best chance for cure.
  • Laparoscopic and robotic surgical techniques allow for smaller incisions, reduced pain, and faster recovery times compared to traditional open surgery.
  • Surgeons aim to handle the tumor carefully without rupturing it, as spillage can lead to cancer cells spreading in the abdomen.
  • For tumors in the stomach, partial or total removal of the stomach may be required; for small intestine tumors, the affected segment is excised.
• Targeted therapy with tyrosine kinase inhibitors
  • Imatinib (Gleevec) is the first-line medication that blocks the KIT protein, stopping the growth signal in most gastrointestinal stromal tumors; standard dose is 400 mg daily, sometimes increased to 800 mg.
  • Sunitinib (Sutent) is used when tumors no longer respond to imatinib; it blocks multiple growth signals and blood vessel formation.
  • Regorafenib (Stivarga) is a third-line option for tumors resistant to both imatinib and sunitinib, targeting multiple kinase pathways.
  • Ripretinib is approved for patients who have received three or more prior treatments, designed to overcome resistance mutations.
• Neoadjuvant therapy (treatment before surgery)
  • Tyrosine kinase inhibitors like imatinib are given before surgery to shrink large or difficult-to-remove tumors, making surgical removal safer and more feasible.
  • This approach can convert an unresectable tumor into one that can be completely removed.
• Adjuvant therapy (treatment after surgery)
  • Imatinib is given for up to three years after surgery in patients at high risk of recurrence to reduce the chance of the cancer coming back.
  • The decision to use adjuvant therapy depends on tumor size, mitotic rate, location, and whether the tumor ruptured during removal.
• Investigational therapies in clinical trials
  • Avapritinib targets the PDGFRA D842V mutation, which is resistant to standard imatinib therapy, showing high response rates in early trials.
  • Combination approaches pairing tyrosine kinase inhibitors with immunotherapy or drugs targeting tumor blood vessels are being explored in Phase I and II studies.
  • Precision medicine strategies use repeated genetic testing to identify new resistance mutations and switch treatments accordingly.

For tumors that have spread to distant parts of the body, called metastatic disease, surgery is usually not curative. However, in selected cases where there are only a few metastatic spots, especially in the liver, removing them surgically may help, particularly if the disease is well-controlled on medication. More commonly, metastatic gastrointestinal stromal tumors are managed with ongoing targeted therapy. The goal shifts from cure to controlling the disease long-term, keeping it stable and preventing symptoms.^[11][14]

Living with gastrointestinal stromal tumor often means staying on medication for months or years. Regular follow-up is essential. After treatment, patients typically have scans (CT or MRI) every three to six months to check for any signs that the tumor is growing back or spreading. If the tumor starts to grow again, doctors reassess the treatment plan, which might mean increasing the drug dose, switching to a different medication, or joining a clinical trial. The five-year survival rate for gastrointestinal stromal tumor varies widely depending on the stage at diagnosis—around 95% for localized tumors, 84% for regional spread, and lower for distant metastases—but these numbers continue to improve as new treatments become available.^[2][23]